{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:37Z","timestamp":1793664817716,"version":"4.5.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy of rituximab (RTX) in the treatment of anti-glomerular basement membrane disease (anti-GBM disease) and to analyze the clinicopathological factors associated with long-term renal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled a total of 66 patients with confirmed anti-GBM disease. Patients were divided into two groups: the control group (n=52) received conventional therapy, including plasma exchange, glucocorticoids, and cyclophosphamide as clinically indicated, and the RTX group (n=14) received RTX in addition to the same conventional therapy. The baseline characteristics, treatment responses, and long-term outcomes were compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The baseline clinical and pathological characteristics were balanced and comparable between the two groups. Although the RTX group demonstrated only numerical advantages in the absolute rate of dialysis independence (50.0% vs. 21.05%, p=0.107) and the 3-year ESRD incidence (42.86% vs. 63.46%, p=0.223), the median time to dialysis independence was significantly shorter in the RTX group compared to the control group (26 vs. 41 days, p=0.009). Kaplan-Meier survival analysis indicated a trend towards higher renal survival in the RTX group, but the difference was not statistically significant (HR\u00a0=\u00a00.640, p=0.169). Prognostic factor analysis indicated that worse baseline renal function, anemia, hypoalbuminemia, elevated BNP, initial dialysis dependency, and absence of cyclophosphamide treatment were associated with progression to ESRD at 3 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with anti-GBM disease, the addition of RTX to standard therapy was associated with accelerated recovery of renal function, as evidenced by a shorter time to dialysis discontinuation. These findings suggest a potential renal recovery benefit of RTX, warranting further validation in larger, prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1835889","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:29:28Z","timestamp":1778477368000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab is associated with accelerated dialysis independence in anti-glomerular basement membrane disease: a retrospective cohort analysis of renal survival"],"prefix":"10.3389","volume":"17","author":[{"given":"Yulin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nephrology, Zhengzhou University First Affiliated Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhengzhou University First Affiliated Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhengzhou University First Affiliated Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhengzhou University First Affiliated Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhengzhou University First Affiliated Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhengzhou University First Affiliated Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Gou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhengzhou University First Affiliated Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhengzhou University First Affiliated Hospital","place":["Zhengzhou, Henan, China"]},{"name":"Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.01.515","article-title":"Anti-glomerular basement membrane disease: broadening the spectrum","volume":"83","author":"Cornell","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103531","article-title":"Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: a systematic review and meta-analysis","volume":"23","author":"Kuang","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.akdh.2024.04.007","article-title":"Anti-glomerular basement membrane disease: recent updates","volume":"31","author":"Bharati","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-84828-0_53","article-title":"Anti-glomerular basement membrane disease - treatment standard","volume":"41","author":"McAdoo","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.09.002","article-title":"Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases","volume":"12","author":"Kattah","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5414\/cn110851","article-title":"Anti-glomerular basement membrane disease: treatment outcome of cyclophosphamide vs. rituximab induction therapy regimen","volume":"98","author":"Jaryal","year":"2022","journal-title":"Clin Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad268","article-title":"Efficacy of rituximab for patients with anti-glomerular basement membrane disease","volume":"39","author":"Chen","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06512-4","article-title":"Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease","volume":"40","author":"Klaus","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2024aqp7s41f","article-title":"Efficacy and safety of rituximab in antiglomerular basement membrane disease","volume":"10","author":"Ivkovic","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2215\/cjn.04290417","article-title":"Predicting outcome in patients with anti-GBM glomerulonephritis","volume":"13","author":"van Daalen","year":"2018","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2024.2400539","article-title":"Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients","volume":"46","author":"Liu","year":"2024","journal-title":"Renal Fail"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Internal Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on Malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:29:29Z","timestamp":1778477369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2026.1835889"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1835889","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1835889"}}